Background
UniProt:P10275 encodes a protein implicated in cellular processes relevant to cancer biology, including cell signaling and regulation. In the context of metastatic prostate cancer, aberrant expression or functional alterations of this protein may contribute to tumor progression and dissemination. However, despite its potential biological relevance, P10275 has not yet been the focus of advanced clinical development programs or targeted therapeutic investigations in metastatic prostate cancer. This positions P10275 as a putative target that warrants further experimental validation to clarify its role and therapeutic potential in this disease setting.
Data-mining rationale
A systematic cross-referencing approach was employed, integrating reviewed human protein entries from UniProt with a broad compendium of 188 microarray datasets from the NCBI Gene Expression Omnibus (GEO). This analysis identified P10275 as recurrently differentially expressed in multiple expression-profiling studies related to metastatic prostate cancer. The datasets supporting this observation include GDS:200285854, GDS:200299093, GDS:200224644, GDS:200248619, and GDS:200149226. These findings suggest that P10275 may be involved in molecular pathways underpinning metastatic progression, making it a candidate for further investigation.
Why prior analyses may have missed this
Many of the GEO datasets containing expression data for P10275 predate the widespread adoption of modern empirical-Bayes statistical methods such as limma, which provide robust control for multiple hypothesis testing via procedures like the Benjamini-Hochberg false discovery rate correction. Earlier analyses may have lacked sufficient statistical power or rigor to detect subtle but biologically meaningful differential expression signals. Consequently, P10275’s potential relevance in metastatic prostate cancer may have been underappreciated or overlooked in prior studies.
Reasoning for further validation
To substantiate P10275 as a putative target in metastatic prostate cancer, several experimental steps are recommended. First, re-analysis of the matched GEO datasets using limma combined with stringent false discovery rate control would clarify the statistical significance and consistency of P10275 differential expression. Second, validation of expression changes by quantitative PCR in independent patient cohorts would provide orthogonal confirmation. Third, assessing tissue specificity and expression patterns in resources such as GTEx and the Human Protein Atlas would contextualize its relevance to prostate tissue and metastatic lesions. Fourth, pathway analysis using tools like STRING or OmniPath could elucidate the molecular networks involving P10275, informing mechanistic hypotheses. Finally, if these validations support its role, evaluation of druggability through databases such as DGIdb and ChEMBL would inform the feasibility of therapeutic targeting. Collectively, these steps would provide a rigorous foundation to determine whether P10275 merits further preclinical and translational research in metastatic prostate cancer.